Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Community Health
Published in: Journal of Community Health 6/2014

Open Access 01-12-2014 | Original Paper

Palivizumab Compliance by Infants in Puerto Rico During the 2009–2010 Respiratory Syncytial Virus Season

Authors: Israel Matías, Inés García-García, Lourdes García-Fragoso, Marta Valcárcel

Published in: Journal of Community Health | Issue 6/2014

Login to get access

Abstract

Respiratory syncytial virus (RSV) is the leading viral pathogen responsible for bronchiolitis and pneumonia in infants. We assessed palivizumab prophylaxis compliance for infants in Puerto Rico. We retrospectively studied data from 868 infants (409 females, 459 males) during the 2009–2010 RSV season. The infants had a mean gestational age of 33 weeks (range 23–41) and a mean birth weight of 1,767 g (range 509–4,120). Only 74 % of the infants with indications received prophylaxis. The main reasons for noncompliance were non-approval by the medical insurance (53 %), parents’ unavailability (31 %), and infant sickness (11 %). Infants with the government medical insurance were more likely to be denied prophylaxis and to receive fewer doses. Parents need to be educated on the importance of RSV prophylaxis. Physicians should be aware that many infants are not being dosed appropriately and that strategies need to be established to improve compliance.
Literature
1.
Light, M., Bauman, J., Mavunda, K., Malinoski, F., & Eggleston, M. (2008). Correlation between respiratory syncytial virus (RSV) test data and hospitalization of children for RSV lower respiratory tract illness in Florida. Pediatric Infectious Disease Journal, 27(6), 512–518.PubMedCrossRef
2.
Meissner, H. C., Long, S. S., & American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. (2003). Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics, 112(6 Pt 1), 1447–1452.PubMedCrossRef
3.
The IMpact-RSV Study Group. (1998). Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics, 102, 531–537.CrossRef
4.
American Academy of Pediatrics. (2009). Respiratory syncytial virus. In L. K. Pickering, C. J. Baker, S. S. Long, & D. Kimberlin (Eds.), Red book. 2009 Report of the committee on infectious diseases (28th ed., pp. 560–569). Elk Grove Village: American Academy of Pediatrics.
5.
Oh, P. I., Lanctôt, K. L., Yoon, A., et al. (2002). Palivizumab prophylaxis for respiratory syncytial virus in Canada: Utilization and outcomes. The Pediatric Infectious Disease Journal, 21(6), 512–518.PubMedCrossRef
6.
Anderson, K. S., Mullally, V. M., Fredrick, L. M., & Campbell, A. L. (2009). Compliance with RSV prophylaxis: Global physicians’ perspectives. Patient Prefer Adherence, 3(3), 195–203.PubMedCentralPubMedCrossRef
7.
Diehl, J. L., Daw, J. R., Coley, K. C., & Rayburg, R. (2010). Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan. Journal of Managed Care Pharmacy, 16(1), 23–31.PubMed
8.
Roberts, J. R., Martines, J., White, S., et al. (2006). Improving compliance for respiratory syncytial virus prophylaxis [abstract 279]. Poster presented at: Southern regional meeting of the American federation for medical research; March 3–5, 2006; Atlanta, GA.
9.
Langkamp, D. L., Hlavin, S. M., & Bowen, M. (2001). Compliance with palivizumab. Pediatrics Research, 49(4 Pt 2):238A. Poster presented at: American Pediatric Society/Society for Pediatric Research/Ambulatory Pediatric Association Annual Meeting; April 27–May 1, 2001; Baltimore, MD.
10.
Stewart, D. L., et al. (2013). Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis. BMC Infectious Diseases, 13, 334.PubMedCentralPubMedCrossRef
11.
Feltes, T. F., Cabalka, A. K., Meissner, H. C., et al. (2003). Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. The Journal of Pediatrics, 143(4), 532–540.PubMedCrossRef
12.
Berger, J., Fensterheim, L., O’Rourke, J., et al. (2003). The importance of Synagis compliance in preventing hospitalizations. Pediatric Research, 53(4 Pt 2), 468A–469A.
13.
Frogel, M., Nerwen, C., Cohen, A., et al. (2008). Prevention of hospitalization due to respiratory syncytial virus: results from the palivizumab outcomes registry. Journal of Perinatology, 28(7), 511–517.PubMedCrossRef
14.
Frogel, M. P., Stewart, D. L., Hoopes, M., Fernandes, A. W., & Mahadevia, P. J. (2010). A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. Journal of Management Care Pharmacy, 16(1), 46–58.
15.
Weiner, L. B., Masaquel, A. S., Polak, M. J., & Mahadevia, P. J. (2012). Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. Journal of Medical Economics, 15(5), 997–1018.PubMedCrossRef
16.
17.
Study Finds Children More Likely to Receive Recommended RSV Medication Doses When Administered Through Specialty Pharmacy. (2011). 20th of October 2011 @ 06:16 | Source: PR Newswire via BioPortfolio.
18.
Langkamp, D. L., & Hlavin, S. M. (2001). Factors predicting compliance with palivizumab in high-risk infants. American Journal of Perinatology, 18(6), 345–352.PubMedCrossRef
Metadata
Title
Palivizumab Compliance by Infants in Puerto Rico During the 2009–2010 Respiratory Syncytial Virus Season
Authors
Israel Matías
Inés García-García
Lourdes García-Fragoso
Marta Valcárcel
Publication date
01-12-2014
Publisher
Springer US
Published in
Journal of Community Health / Issue 6/2014
Print ISSN: 0094-5145
Electronic ISSN: 1573-3610
DOI
https://doi.org/10.1007/s10900-014-9877-z

Other articles of this Issue 6/2014

Journal of Community Health 6/2014 Go to the issue

Original Paper

Edentulism Associates with Worse Cognitive Performance in Community-Dwelling Elders in Rural Ecuador: Results of the Atahualpa Project

Original Paper

Influenza Knowledge, Attitude, and Behavior Survey for Grade School Students: Design and Novel Assessment Methodology

Original Paper

Socio-Demographic Correlates of Injection Drug Use Among Male Drug Users: A Cross Sectional Study in Nepal

Original Paper

The Relationship Between Diabetes Attitudes and Treatment Among Free Clinic Patients and Volunteers

Original Paper

Predicting Outdoor Recreation Area Use in a Southeastern US County: A Signal Detection Analysis

Original Paper

Smallpox Inoculation (Variolation) in East Africa with Special Reference to the Practice Among the Boran and Gabra of Northern Kenya